ADAR1 Capital Management LLC Purchases 157,070 Shares of Ventyx Biosciences, Inc. $VTYX

Key Points

• ADAR1 Capital Management LLC increased its stake in Ventyx Biosciences by 126.1%, acquiring 157,070 shares for a total of 281,600 shares, valued at $324,000.
• Wall Street analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with a consensus price target of $7.50.
• Shares of Ventyx Biosciences opened at $2.40, after reporting earnings of ($0.38) EPS, exceeding analyst expectations by $0.07.

ADAR1 Capital Management LLC boosted its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 126.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 281,600 shares of the company's stock after purchasing an additional 157,070 shares during the quarter. ADAR1 Capital Management LLC owned about 0.40% of Ventyx Biosciences worth $324,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new stake in Ventyx Biosciences in the 1st quarter worth $28,000. Bank of America Corp DE increased its holdings in shares of Ventyx Biosciences by 376.4% in the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock worth $9,359,000 after buying an additional 3,376,446 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Ventyx Biosciences in the 4th quarter worth about $276,000. Millennium Management LLC increased its holdings in shares of Ventyx Biosciences by 369.7% in the 4th quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock worth $2,807,000 after buying an additional 1,008,760 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of Ventyx Biosciences by 79.8% in the 4th quarter. Two Sigma Investments LP now owns 476,291 shares of the company's stock worth $1,043,000 after buying an additional 211,421 shares during the last quarter. Hedge funds and other institutional investors own 97.88% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Ventyx Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock traded down $0.08 during trading hours on Friday, reaching $2.52. The company's stock had a trading volume of 429,444 shares, compared to its average volume of 569,336. The firm has a 50 day moving average price of $2.65 and a 200-day moving average price of $1.92. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $3.39. The stock has a market cap of $179.70 million, a P/E ratio of -1.50 and a beta of 0.95.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07. As a group, sell-side analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.